INSURANCE/HEALTH: Provides relative to coverage for orally administered anti-cancer medications (EN +$66,367 SG EX See Note)

Header metadata was updated to reflect the 'Original' bill version with a new reference number (HLS 26RS-1078) instead of 'Enrolled', and page numbers were adjusted to match the original draft layout.

The maximum cost-sharing limit for oral anti-cancer medications was reduced from $100 to $80 per filled prescription.

Insurance plans are now prohibited from using accumulator or maximizer programs that fail to credit manufacturer discounts toward a patient's deductible or out-of-pocket maximum.

The list of bill sponsors was updated to include Representative Chassion in addition to Representative Freeman.

The document status was updated from 'Re-Engrossed' to 'Enrolled', indicating the bill has been passed by both legislative houses and is ready for signature.

Prohibited practices were expanded to include prior authorizations, dollar limits, formulary classifications, and other utilization management requirements that increase out-of-pocket costs or restrict access.

The restrictions on cost-sharing now apply to high-deductible health plans that are eligible for use with Health Savings Accounts (HSAs) and Medical Savings Accounts (MSAs).

Protection against cost-sharing limits was extended to include intravenously administered or injected anti-cancer medications, previously limited to orally administered medications.

The definition of 'cost-sharing requirements' was updated to explicitly list prior authorizations, dollar limits, and formulary classifications as included items.

Minor formatting and numbering adjustments were made throughout the document, including updating the bill status to 'Re-Engrossed' and correcting line numbering.

Restored the definition of 'cost-sharing requirements' to include copayments, coinsurance, deductibles, and other amounts paid by the covered person, which was previously missing due to a deletion error.